31-45 of 347
Navigating the Modern PsA Treatment Landscape
Living RheumNavigating the Modern PsA Treatment Landscape
Targeting Psoriasis at the Source: New Evidence for Interferon Receptor Therapies
DermConsultTargeting Psoriasis at the Source: New Evidence for Interferon Receptor Therapies
Assessing the Role of Metabolic Factors in Psoriasis Management
AudioAbstractsAssessing the Role of Metabolic Factors in Psoriasis Management
Recognizing PSO-HS as a Distinct Subset with Shared Genetic Risk
DermConsultRecognizing PSO-HS as a Distinct Subset with Shared Genetic Risk
Unmasking Psoriasis in Skin of Color: Clinical Clues and Care Strategies
DermConsultUnmasking Psoriasis in Skin of Color: Clinical Clues and Care Strategies
Pediatric Psoriasis in Focus: Emerging Insights on Immune and Obesity Drivers
On the Frontlines of PsoriasisPediatric Psoriasis in Focus: Emerging Insights on Immune and Obesity Drivers
- advertisement
TYK2 Inhibition with Zasocitinib Delivers Early Benefit Across PsA Domains
DermConsultTYK2 Inhibition with Zasocitinib Delivers Early Benefit Across PsA Domains
Targeting Head and Neck Atopic Dermatitis: Long-Term Outcomes with Tralokinumab
DermConsultTargeting Head and Neck Atopic Dermatitis: Long-Term Outcomes with Tralokinumab
Chronic Hand Eczema: Guideline-Based Strategies for Diagnosis and Management
DermConsultChronic Hand Eczema: Guideline-Based Strategies for Diagnosis and Management
Examining Delgocitinib for Chronic Hand Eczema: Results from the DELTA Trials
DermConsultExamining Delgocitinib for Chronic Hand Eczema: Results from the DELTA Trials
Applying Guidelines to Chronic Hand Eczema Care: A Case-Based Approach
DermConsultApplying Guidelines to Chronic Hand Eczema Care: A Case-Based Approach
Rewriting the Rules of Psoriasis Severity: A Global Shift Toward Impact-Driven Care
FCDC Action CenterRewriting the Rules of Psoriasis Severity: A Global Shift Toward Impact-Driven Care
- advertisement
How Systemic Psoriasis Therapies Influence the Risk of New or Recurrent MACEs
FCDC Action CenterHow Systemic Psoriasis Therapies Influence the Risk of New or Recurrent MACEs
Improving Psoriatic Disease Care Through Dermatology–Rheumatology Clinics
FCDC Action CenterImproving Psoriatic Disease Care Through Dermatology–Rheumatology Clinics
Combination Therapy for Plaque Psoriasis: A Reappraisal of Cyclosporine and Acitretin
FCDC Action CenterCombination Therapy for Plaque Psoriasis: A Reappraisal of Cyclosporine and Acitretin
